GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » PB Ratio

Pfizer (Pfizer) PB Ratio

: 1.61 (As of Today)
View and export this data going back to 1951. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-18), Pfizer's share price is $25.39. Pfizer's Book Value per Share for the quarter that ended in Dec. 2023 was $15.77. Hence, Pfizer's PB Ratio of today is 1.61.

Good Sign:

Pfizer Inc stock PB Ratio (=1.61) is close to 10-year low of 1.55

The historical rank and industry rank for Pfizer's PB Ratio or its related term are showing as below:

PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.55   Med: 2.98   Max: 4.41
Current: 1.61

During the past 13 years, Pfizer's highest PB Ratio was 4.41. The lowest was 1.55. And the median was 2.98.

PFE's PB Ratio is ranked better than
58.36% of 963 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs PFE: 1.61

During the past 12 months, Pfizer's average Book Value Per Share Growth Rate was -7.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 11.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 9.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 3.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pfizer was 49.70% per year. The lowest was -7.80% per year. And the median was 5.75% per year.

Back to Basics: PB Ratio


Pfizer PB Ratio Historical Data

The historical data trend for Pfizer's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 3.24 4.30 3.01 1.83

Pfizer Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.01 2.28 2.09 1.93 1.83

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's PB Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's PB Ratio falls into.



Pfizer PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Pfizer's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=25.39/15.766
=1.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Pfizer  (NYSE:PFE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Pfizer PB Ratio Related Terms

Thank you for viewing the detailed overview of Pfizer's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (Pfizer) Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff officer: Executive Vice President 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler officer: Senior Vice President PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten officer: Senior Vice President 5 GIRALDA FARMS, MADISON NJ 07940
David M Denton officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao officer: Executive Vice President C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson officer: Executive Vice President PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie officer: Executive Vice President C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman officer: Senior Vice President 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang officer: Group President 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young officer: Business Unit President C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017

Pfizer (Pfizer) Headlines

From GuruFocus

Pfizer Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc To Host Investment Analysts Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc to Discuss Climate Action Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc To Acquire Seagen Inc Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc to Review Oral GLP-1 Data Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024